<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02430740</url>
  </required_header>
  <id_info>
    <org_study_id>AMH1</org_study_id>
    <nct_id>NCT02430740</nct_id>
  </id_info>
  <brief_title>Tailored Ovarian Stimulation Based on BMI, AMH, AFC</brief_title>
  <official_title>Multicentric Randomized Controlled Study to Determine a Tailored Strategy for Controlled Ovarian Stimulation in IVF Based on AMH, BMI and AFC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objective is to develop a tailored based strategy for ovarian stimulation in IVF
      patients using AMH, BMI, antral follicle count (AFC).

      300 patients will be randomized in 2 arms:

        1. control group: standard care rec FSH.

        2. study group: modified dose of Rec FSH based on AFC with a correction factor based on BMI
           and basal AMH level.

      Primary endpoints: number of mature follicles and eggs collected at egg retrieval; amount of
      rec FSH used.

      Secondary endpoints: fertilization rate; cleavage rate; clinical pregnancy rate; inhibin B
      and AMH levels during ovarian stimulation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study objective is to develop a tailored based strategy for ovarian stimulation in IVF
      patients using AMH, BMI, AFC and inhibin B.

      300 patients will be stimulated with rec FSH and an antagonist pituitary inhibition protocol,
      and randomized (at random computer generated numbers) in 2 arms:

        1. control group: standard care recFSH based on age, basal FSH and AFC.

        2. study group: modified dose of Rec FSH based on AFC with a correction factor based on BMI
           and basal AMH level.

      FSH administration: 20IU per antral follicle (from 2-5mm) corrected as follows:

      Correction factor for

      AMH:

      &lt;1 pMol/L X4 1-6 pMol/L X2 7-18 pMol/L X1 &gt;18 pMol/L X0.5 BMI 16.5-18.5 X0.75 18.5-25 X1
      25-30 X1.25 30-35 X1.5 35-40 X2 Primary endpoints: number of mature follicles and eggs
      collected at egg retrieval; amount of rec FSH used.

      Secondary endpoints: fertilization rate; cleavage rate; clinical pregnancy rate; inhibin B
      and AMH levels during ovarian stimulation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of mature follicles</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>number of oocytes retrieved</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>rec FSH dose used</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>fertilization rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cleavage rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical pregnancy rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AMH level during stimulation</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inhibin B level during stimulation</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>standard care recFSH</description>
  </arm_group>
  <arm_group>
    <arm_group_label>study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>modified dosage of recFSH for controlled ovarian stimulation based on AMH, BMI and AFC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recFSH</intervention_name>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>study group</arm_group_label>
    <other_name>Gonal F</other_name>
    <other_name>Puregon</other_name>
    <other_name>Fostimon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  female infertile patients eligible for IVF treatment

        Exclusion Criteria:

          -  polycystic ovaries

          -  untreated thyroid pathology

          -  hypogonadotropic hypogonadism

          -  untreaed hyperprolactinemia

          -  study drug hypersensitivity

          -  previous OHSS

          -  unilateral ovariectomy

          -  genital malformation

          -  BMI&gt;40
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>43 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christine Wyns, MD, PhD</last_name>
    <phone>003227649501</phone>
    <email>christine.wyns@uclouvain.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Céline Pirard, Md, PhD</last_name>
    <phone>003227644116</phone>
    <email>celine.pirard@uclouvain.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cliniques universitaires Saint Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Wyns, MD, PhD</last_name>
      <phone>003227649501</phone>
      <email>christine.wyns@uclouvain.be</email>
    </contact>
    <contact_backup>
      <last_name>Céline Pirard, Md, PhD</last_name>
      <phone>003227649501</phone>
      <email>celine.pirard@uclouvain.be</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2015</study_first_submitted>
  <study_first_submitted_qc>April 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2015</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</investigator_affiliation>
    <investigator_full_name>Wyns</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Fertilization in Vitro</keyword>
  <keyword>antagonist protocol</keyword>
  <keyword>antral follicle count</keyword>
  <keyword>Anti-Mullerian Hormone</keyword>
  <keyword>Reproductive Techniques, Assisted</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

